Spectrum Pharmaceuticals, Inc. product portfolio
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Home > Product Portfolio
Development Pipeline

Poziotinib

  • EGFR or HER2 Exon 20 Insertion Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Phase 1 Phase 2 Phase 3 Approved
  • HER2-Positive Metastatic Breast Cancer
    Phase 1 Phase 2 Phase 3 Approved
  • HER2-Positive Advanced or Metastatic Breast Cancer in Combination With T-DM1
    Phase 1 Phase 2 Phase 3 Approved
For more information click here.

Eflapegrastim

  • Chemotherapy-Induced Neutropenia (ADVANCE)
    Phase 1 Phase 2 Phase 3 Approved
  • Chemotherapy-Induced Neutropenia (RECOVER)
    Phase 1 Phase 2 Phase 3 Approved
For more information click here.

Apaziquone

  • Non-Muscle Invasive Bladder Cancer (CONQUER)
    Phase 1 Phase 2 Phase 3 Approved
For more information click here.

Belinostat (Beleodaq®)

  • Front-Line Peripheral T-Cell Lymphoma (PTCL)
    Phase 1 Phase 2 Phase 3 Approved

Pralatrexate (Folotyn®)

  • Front-Line Peripheral T-Cell Lymphoma (PTCL)
    Phase 1 Phase 2 Phase 3 Approved
Developmental Trial Pivotal Trial

Back to top

Poziotinib Eflapegrastim Apaziquone